HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Ovotesticular disorder of sex development — Clinical Guidelines

Overview

Ovotesticular disorder of sex development (DSD) refers to conditions characterized by the presence of both testicular and ovarian tissue in an individual, leading to ambiguous genitalia and complex reproductive anatomy. 1 3 5

Diagnosis

Comprehensive clinical evaluation including karyotyping and hormonal assessments.

Imaging studies (ultrasound, MRI) to assess gonadal structure and location.

Genetic testing to identify specific mutations or syndromes (e.g., MIRAGE syndrome, POR deficiency).

Multidisciplinary team assessment including endocrinologists, geneticists, and psychologists. 2 3 10

Management

Surgical intervention: Early surgical correction of ambiguous genitalia, guided by multidisciplinary team recommendations.

Hormonal therapy: Sex steroid replacement tailored to the individual's genetic sex and developmental stage.

Psychosocial support: Regular psychological evaluations and counseling for both patients and families.

Long-term monitoring: Regular follow-up for gonadal malignancy surveillance, particularly in those with increased risk. 1 2 5

Special Populations

Pediatrics: Early multidisciplinary assessment and management crucial; involvement of pediatric endocrinologists essential. 2 7

Comorbidities: Special attention to associated conditions like MIRAGE syndrome or POR deficiency requiring tailored management strategies. 3 10

Key Recommendations

Assessment by experienced clinicians: Any child with suspected DSD should be assessed by an experienced clinician knowledgeable in DSD conditions. (Evidence: Strong 2 7)

Multidisciplinary team involvement: Prompt access to a multidisciplinary team including specialists in endocrinology, genetics, psychology, and nursing is essential for comprehensive care. (Evidence: Strong 2 5)

Long-term oncologic surveillance: Patients with DSD should undergo regular monitoring for gonadal tumors, especially those with increased risk profiles. (Evidence: Moderate 1)

References

1 Peard LM, Morin J, Flores V, Graham K, Taylor AS, Pope JC et al.. Gonadal tumors in a contemporary cohort of patients with differences in sex development undergoing surgery - A multi-site study from the Pediatric Urologic Oncology Working Group of the societies for pediatric urology. Journal of pediatric urology 2023. link 2 Ahmed SF, Achermann J, Alderson J, Crouch NS, Elford S, Hughes IA et al.. Society for Endocrinology UK Guidance on the initial evaluation of a suspected difference or disorder of sex development (Revised 2021). Clinical endocrinology 2021. link 3 Shima H, Hayashi M, Tachibana T, Oshiro M, Amano N, Ishii T et al.. MIRAGE syndrome is a rare cause of 46,XY DSD born SGA without adrenal insufficiency. PloS one 2018. link 4 Kranenburg LJC, Reerds STH, Cools M, Alderson J, Muscarella M, Magrite E et al.. Global Application of the Assessment of Communication Skills of Paediatric Endocrinology Fellows in the Management of Differences in Sex Development Using the ESPE E-Learning.Org Portal. Hormone research in paediatrics 2017. link 5 Gomez-Lobo V, Oelschlager AA. Gynecological challenges in the diagnosis and care of patients with DSD: The role of the obstetrician gynecologist in the multidisciplinary approach to the patient. American journal of medical genetics. Part C, Seminars in medical genetics 2017. link 6 Rossi M, Vasiljevic A, Labalme A, Dijoud F, Mallet-Motak D, Petcu CA et al.. A novel disorder of sex development, characterized by progressive regression of testicular function and cystic leukoencephalopathy. American journal of medical genetics. Part A 2017. link 7 Ahmed SF, Achermann JC, Arlt W, Balen A, Conway G, Edwards Z et al.. Society for Endocrinology UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development (Revised 2015). Clinical endocrinology 2016. link 8 Austin J, Tamar-Mattis A, Mazur T, Henwood MJ, Rossi WC. Disorders of sex development-when and how to tell the patient. Pediatric endocrinology reviews : PER 2011. link 9 Brain CE, Creighton SM, Mushtaq I, Carmichael PA, Barnicoat A, Honour JW et al.. Holistic management of DSD. Best practice & research. Clinical endocrinology & metabolism 2010. link 10 Sahakitrungruang T, Huang N, Tee MK, Agrawal V, Russell WE, Crock P et al.. Clinical, genetic, and enzymatic characterization of P450 oxidoreductase deficiency in four patients. The Journal of clinical endocrinology and metabolism 2009. link 11 Rosenquist TA, Kimble J. Molecular cloning and transcript analysis of fem-3, a sex-determination gene in Caenorhabditis elegans. Genes & development 1988. link

Ovotesticular disorder of sex development